05 Oct, 2022 Alnylam Presents at OTS 2022 Annual Meeting

We presented on platform and clinical results at the Oligonucleotide Therapeutics Society (OTS) 2022 18^th Annual Meeting held in Phoenix, Arizona on October 2-5, 2022.

Human Genetics as an Enabler of RNAi Therapeutics – Paul Nioi
Phase 3 study, HELIOS-A, in hATTR Patients Evaluating a Single Dose Regimen – Gabriel Robbie
Toxicology and DMPK Assessment of siRNA Therapeutics – Joe Dybowski

30 Sep, 2022 Results from APOLLO-B Phase 3 Study of Patisiran Presented as HFSA

At the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022, we presented results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Read the press release
Maurer, et al. “Primary Results from APOLLO-B, a Phase 3 Study of Patisiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy”
Kale, et al. “Exploratory Analyses from APOLLO-B, a Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy”

22 Sep, 2022 New Analysis from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at IPNA

Results from a post-hoc analysis of patients on hemodialysis in the ongoing ILLUMINATE-C Phase 3 open-label study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) were presented at the International Pediatric Nephrology Association (IPNA) Congress (Sept. 7-11, 2022).

Michael, et al. “Relationship of Baseline Weight and Response to Lumasiran in Patients With Primary Hyperoxaluria Type 1 on Hemodialysis”

08 Sep, 2022 Results from APOLLO-B Phase 3 Study of Patisiran Presented at ISA

During a late-breaker session at the 18^th International Symposium on Amyloidosis, we presented results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Read the press release
Maurer, et al. “Primary Results from APOLLO-B, a Phase 3 Study of Patisiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy”

(more…)

29 Aug, 2022 New Results from Phase 2 Study of Investigational Cemdisiran Presented at EMCHD

During the 18^th European Meeting on Complement in Human Disease (EMCHD), taking place August 26-28, 2022, we presented new results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is being developed in collaboration with Regeneron Pharmaceuticals for the treatment of immunoglobulin A nephropathy.

Read the press release
Barratt, et al. “Results from the Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy”

02 Aug, 2022 ILLUMINATE-B Phase 3 Results for OXLUMO® (lumasiran) Published in Pediatric Nephrology

Results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were published online in Pediatric Nephrology.

Read the paper in the Pediatric Nephrology

23 Jul, 2022 HELIOS-A 18-Month Phase 3 Results for AMVUTTRA™ (vutrisiran) Published in Amyloid

Eighteen-month efficacy and safety results from the HELIOS-A Phase 3 study of AMVUTTRA™ (vutrisiran), an RNAi therapeutic recently approved in the U.S. for adults with the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, were published in Amyloid.

Read the paper in Amyloid

20 Jul, 2022 ILLUMINATE-C Phase 3 Results for Lumasiran Published in American Journal of Kidney Diseases

Results from the six-month primary analysis of the ongoing ILLUMINATE-C Phase 3 study of lumasiran in patients of all ages with primary hyperoxaluria type 1 (PH1) and advanced kidney disease were published online in the American Journal of Kidney Diseases.

Read the paper in the American Journal of Kidney Diseases